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RESEARCH
Transcriptomic profiling and quantitative 
high-throughput (qHTS) drug screening 
of CDH1 deficient hereditary diffuse gastric 
cancer (HDGC) cells identify treatment leads 
for familial gastric cancer
Ina Chen1,2, Lesley Mathews‑Greiner3, Dandan Li1, Abisola Abisoye‑Ogunniyan1,4 , Satyajit Ray5, 
Yansong Bian1, Vivek Shukla1, Xiaohu Zhang3, Raj Guha3, Craig Thomas3, Berkley Gryder6, Athina Zacharia1, 
Joal D. Beane7, Sarangan Ravichandran8, Marc Ferrer3 and Udo Rudloff1*
Abstract 
Background: Patients with hereditary diffuse gastric cancer (HDGC), a cancer predisposition syndrome associated 
with germline mutations of the CDH1 (E‑cadherin) gene, have few effective treatment options. Despite marked differ‑
ences in natural history, histopathology, and genetic profile to patients afflicted by sporadic gastric cancer, patients 
with HDGC receive, in large, identical systemic regimens. The lack of a robust preclinical in vitro system suitable for 
effective drug screening has been one of the obstacles to date which has hampered therapeutic advances in this rare 
disease.
Methods: In order to identify therapeutic leads selective for the HDGC subtype of gastric cancer, we compared 
gene expression profiles and drug phenotype derived from an oncology library of 1912 compounds between gastric 
cancer cells established from a patient with metastatic HDGC harboring a c.1380delA CDH1 germline variant and 
sporadic gastric cancer cells.
Results: Unsupervised hierarchical cluster analysis shows select gene expression alterations in c.1380delA CDH1 
SB.mhdgc‑1 cells compared to a panel of sporadic gastric cancer cell lines with enrichment of ERK1–ERK2 (extracel‑
lular signal regulated kinase) and IP3 (inositol trisphosphate)/DAG (diacylglycerol) signaling as the top networks in 
c.1380delA SB.mhdgc‑1 cells. Intracellular phosphatidylinositol intermediaries were increased upon direct measure 
in c.1380delA CDH1 SB.mhdgc‑1 cells. Differential high‑throughput drug screening of c.1380delA CDH1 SB.mhdgc‑1 
versus sporadic gastric cancer cells identified several compound classes with enriched activity in c.1380 CDH1 
SB.mhdgc‑1 cells including mTOR (Mammalian Target Of Rapamycin), MEK (Mitogen‑Activated Protein Kinase), c‑Src 
kinase, FAK (Focal Adhesion Kinase), PKC (Protein Kinase C), or TOPO2 (Topoisomerase II) inhibitors. Upon additional 
drug response testing, dual PI3K (Phosphatidylinositol 3‑Kinase)/mTOR and topoisomerase 2A inhibitors displayed up 
to >100‑fold increased activity in hereditary c.1380delA CDH1 gastric cancer cells inducing apoptosis most effectively 
in cells with deficient CDH1 function.
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Background
Hereditary diffuse gastric cancer (HDGC) is an auto-
somal dominant cancer susceptibility syndrome due to 
germline mutations within the E-cadherin (CDH1) gene 
locus cadherin (CDH1; NM_004360) [1, 2]. HDGC is 
clinically defined by the familial occurrence of early-onset 
diffuse gastric cancer (DGC) and lobular breast cancer 
[2–4]. Of the 26,370 cases of gastric cancer expected to 
be diagnosed in the United States in 2016, 5 to 10 percent 
arise in a familiar context and about 34–45% of these are 
due to CDH1 germline mutations [4, 5]. CDH1 germline 
mutations are most commonly truncating CDH1 variants 
affecting the extracellular domains of the E-cadherin gene 
leading to loss of CDH1 expression, followed by missense 
and splice site variants and, infrequently, large genomic 
deletions [2]. CDH1 mutations are heterozygous and dis-
persed across the 16 exons of CDH1 [6]. Hypermethyla-
tion of the CDH1 promotor of the unaffected wild type 
allele and loss of heterozygosity are considered the most 
common second hit mechanisms of CDH1 inactivation 
and loss [7]. Male CDH1 mutation carriers have by the 
age 80 a cumulative incidence of gastric cancer of 70%, 
female mutation carriers a risk of 56% of gastric and 42% 
for lobular breast cancer [2]. Risk-reducing gastrectomy 
and breast MRI surveillance is currently advised for all 
patients with CDH1 germline gene mutations [4].
The natural history and clinical course of HDGC 
patients differs significantly from patients afflicted by 
sporadic gastric cancer: HDGC harbors a unique early 
stage (T1a) characterized by foci of intramucosal signet-
ring cell carcinoma confined to the lamina propria [4, 
8]. The number of these foci of early invasive cells may 
exceed one hundred and are thought to originate as an 
early event from displaced daughter cells of neoplastic 
cells with reduced CDH1 expression at the upper neck of 
gastric glands which have lost their physiological epithe-
lial localization due to loss of cytoskeletal organization, 
cell plasticity and cell polarity [8, 9]. Further invasion 
beyond the gastric mucosa is associated with poor dif-
ferentiation, Src kinase activation, and epithelial-to-mes-
enchymal transformation [10]. While the natural history 
of these early intramucosal lesions is incompletely under-
stood, it is thought that they might be relatively indo-
lent and that there is, unlike in sporadic gastric cancer, 
a latency period of possibly many years towards further 
progression [4]. Clinically, patients with advanced famil-
ial gastric cancer and a genetic loss of CDH1 have a 
worse clinical outcome compared to patients with epige-
netic silencing or no CDH1 alteration [11].
Despite these molecular, histopathological, and clini-
cal differences, patients with HDGC receive, in large, 
the same, largely ineffective cytotoxic chemotherapy 
regimens as sporadic gastric cancer patients. In contrast, 
recent differential gene expression, synthetic lethality, 
and high throughput drug screening studies in isogenic 
E-cadherin deficient (−/−) breast MCF10A cells identi-
fied several select genetic and pharmacological vulner-
abilities in CDH1(−/−) mutant cells [12]. While some 
of the observed activity profiles in CDH1-deficient cells, 
like select sensitivities to Src kinase in the CDH1(−/−) 
mutant MCF10A isoform, were in line with early signal-
ing perturbations observed in T1a cancers of gastrectomy 
specimens of HDGC patients, other signaling aberrations 
observed in clinical specimens later in the transition of 
invasion beyond the gastric mucosa, like FAK and STAT3 
kinase activation, were not found to be associated with 
select drug sensitivities in the MCF10A CDH1(−/−) 
in  vitro system [10, 12]. As the MCF10A CDH1(−/−) 
isogenic system captures predominantly early vulnerabil-
ities with predominantly chemopreventative translational 
value, it is thus not known if the synthetic lethalities and 
drug sensitivities discovered to selectively occur in the 
CDH1(−/−) mutants capture vulnerabilities of E-cad-
herin deficient gastric cancers in a more evolved stage 
which might harbor greater therapeutic value.
To develop new therapeutic strategies for HDGC 
patients, we compared drug sensitivity profiles derived 
from a dose response quantitative high throughput drug 
(qHTS) screens of 1912 oncology compounds between 
c.del1380A CDH1 gastric cancer cells derived from a 
HDGC patient, and wild type CDH1 gastric cancer cells 
derived from a sporadic gastric cancer patient. We com-
bined the differential pharmacological responses with 
gene expression profiles between c.del1380A CDH1 
and a cohort of sporadic gastric cancer cells. Increased 
ERK1/2 and phosphatidylinositol 4,5-bisphosphate 
(PIP2)-mediated signaling in c.1380delA CDH1 cells 
was accompanied by increased sensitivities to mTOR, 
Conclusion: Integrated pharmacological and transcriptomic profiling of hereditary diffuse gastric cancer cells with 
a loss‑of‑function c.1380delA CDH1 mutation implies various pharmacological vulnerabilities selective to CDH1‑
deficient familial gastric cancer cells and suggests novel treatment leads for future preclinical and clinical treatment 
studies of familial gastric cancer.
Keywords: Hereditary diffuse gastric cancer (HDGC), High throughput drug screening, Therapeutic leads, c.1380delA 
CDH1 gastric cancer cells, Differential gene expression profiling
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AKT, MEK, protein kinase C (PKC) and topoisomer-
ase II (TOPO2) signaling inhibition. We also observed 
increased sensitivities to compounds belonging to ALK 
(Anaplastic Lymphoma receptor tyrosine Kinase), FAK 
and aurora kinase inhibitors, sensitivity to epidermal 
growth factor receptor (EGFR) and Janus Kinase (JAK) 
inhibitors in both c.del1380A CDH1 and sporadic gastric 
cancer cells, and relative resistance to BRD4 inhibitors in 
c.del1380A CDH1. Together, this study integrates tran-
scriptomic aberrations with drug cytotoxic responses in 
patient-derived c.del1380A CDH1 HDGC versus CDH1 
wild type sporadic gastric cancer cells providing new 
therapeutic leads for the difficult to treat CDH1 mutant 
familial subtype of gastric cancer.
Methods
Patient
The patient is a 44-year-old male who presented to the 
NIH surgical service for management of metastatic dif-
fuse gastric cancer. All genetic counselling, clinical care, 
and interventions were carried out under Institutional 
Review Board (IRB)-approved protocol NCI-09-C-0079 
with patient providing written informed consent. His sis-
ter and father were diagnosed with gastric cancer at the 
age of 44 and 72, respectively (Fig.  1). The patient, and 
other family members, previously underwent germline 
CDH1 mutation testing and found to harbor a heterozy-
gous c.1380delA variant in the CDH1 locus. The patient 
had extensive ascites upon presentation. A palliative 
paracentesis was performed; cytological specimen was 
collected (6  L hemorrhagic ascites) and later used to 
establish the described patient-derived cell culture line 
of hereditary diffuse gastric cancer. Given the advanced 
stage of the patient’s cancer and his poor performance 
status, the patient and the NIH surgical team decided 
to opt for palliative care and the patient expired shortly 
thereafter.
Establishment of patient‑derived hereditary diffuse gastric 
cancer cell line
Cell suspensions created from the patient’s ascites were 
injected subcutaneously into female SCID mice (250,000 
Fig. 1 Pedigree of family with hereditary diffuse gastric cancer harboring c.1380delA germline mutation of the CDH1 gene. Squares indicate males; 
circles indicate females. Symbols with a shaded portion indicate individuals whom have been diagnosed with cancer. Type of cancer and age at 
diagnosis are indicated, symbols with slashes indicate deceased family members
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cells per animal). When the tumor grew to approximately 
2  cm2, xenografts were harvested, digested, and sus-
pended in ultra-low attachment tissue culture flasks until 
formation of spheroid bodies was observed [13]. Tumor-
derived spheroids were then dissociated, re-seeded onto 
standard tissue culture flasks and grown for several pas-
sages in DMEM/F12 (Crystalgen, Commack, NY) with 
10% HyClone fetal bovine serum (Thermo Scientific, 
Waltham, MA). Cells were passaged every 4–5  days by 
lifting them with 0.05% Trypsin (Gibco, Grand Island, 
NY), frozen after three passages, and not allowed to grow 
beyond 10 passaging cycles. For the spheroid assay, 1000 
dissociated c.1380delA CDH1 SB.mhdgc-1 cells/mL were 
seeded in media conditions above in nonadherent 6-well 
plates coated with hydrogel (Corning Life Sciences, 
Chelmsford, MA) and spheroid formation observed for 
6 weeks [13]. Media was replaced every 6–8 days.
Cell lines and reagents
Establishment of tissue culture line SB.msgc-1 at our 
institution was previously reported [14]. Gastric cancer 
lines SNU-1, SNU-5, SNU-16, KATO III, AGS, NCI-N87, 
and BxPC-3 and HeLa cells were purchased from ATCC 
(American Type Culture Collection (ATCC), Manas-
sas, VA). Antibodies for immunofluorescence studies 
included mouse anti-E-cadherin primary antibody (BD 
Transduction Laboratories, San Jose, CA), CEA/CD66e 
antibody (Cell Signaling, Danvers, MA), mouse IgG2a, 
κ (BD Biosciences, San Jose, CA), mouse (G3A1) mAb 
IgG1 isotype control (Cell Signaling, Danvers, MA), and 
Alexa Fluor ® 488 goat anti-mouse IgG (H + L) antibody 
(Life Technologies, Frederick, MD). Etoposide, mitox-
antrone, and PI-103 were purchased from SelleckChem 
(Houston, TX).
Spectral karyotyping
Metaphases of SB.mhdgc-1 cells were arrested by incu-
bation with Colcemid (KaryoMax ® Colcemid Solution, 
Invitrogen, Carlsbad, CA) (10  μg/mL) 3  h prior to har-
vest. Cells were collected and treated with hypotonic 
solution (KCL 0.075  M) for 15  min at 37  °C and fixed 
with methanol: acetic acid 3:1. Slides were prepared and 
aged overnight for use in SKY analysis and FISH. Meta-
phases were hybridized with the 24-color human SKY 
paint kit (Applied Spectral Imaging Inc. (ASI), Carlsbad, 
CA) according to manufacturer’s protocol. Hybridization 
was carried out in a humidity chamber at 37 °C for 16 h. 
A post-hybridization rapid wash procedure was used 
with 0.4  ×  SSC at 72  °C for 4  min. Spectral images of 
the hybridized metaphases were acquired using a SD301 
SpectraCubeTM system (ASI, Carlsbad, CA) mounted on 
top of an epi-fluorescence microscope Axioplan 2 (Zeiss, 
Thornwood, NY). Images were analyzed using Spectral 
Imaging 6.0 acquisition software (ASI, Carlsbad, CA). A 
minimum of 10 mitoses of comparable staining intensity 
and quality was examined per cell line and analyzed for 
chromosomal abnormality.
Immunofluorescence microscopy
Approximately 50,000 were centrifuged onto a glass 
slide with Rotofix 32 A centrifuge (Hettich Lab Tech-
nology, Tuttlingen, Germany) and fixed in methanol 
at room temperature for 2  min. Cells were permeabi-
lized in 0.25% TritonX-100 and blocked with 5% normal 
goat serum in PBS at room temperature in a humidi-
fied chamber for 2 h. Slides were incubated with mouse 
monoclonal anti-human E-cadherin and CEA/CD66e 
primary antibody, or mouse IgG2A κ or mouse G3A1 
IgG1 isotype control overnight in 4 °C. Phosphoinositide 
signaling intermediaries were measured with anti-phos-
phatidylinositol 4,5-bisphosphate (PIP2) (Cat. #Z-P045) 
and anti-phosphatidylinositol 3,4,5-trisphosphate (PIP3) 
(Cat. #Z-P345; Echelon Biosciences Inc., Salt Lake City, 
UT) monoclonal antibodies. Alexa  Fluor® 488 goat anti-
mouse IgG (H + L) secondary antibody was then applied 
for 1 h at room temperature. Slides were mounted with 
Vectashield/DAPI (Vector Laboratories, Burlingame, 
CA). Images were captured using a Zeiss LSM 510 UV 
(E-cadherin images) or Zeiss LSM 780 (CEA images) 
confocal microscope (Zeiss, Thornwood, NY).
CDH1 mutation testing
DNA (500  ng) from both spheroid cultures and 
SB.mhdgc-1 monolayer cells was performed using the 
previously described parallel sequencing OncoVar assay 
[15]. In brief, Illumina paired-end adaptors were ligated 
to  ~300  bp genomic DNA fragments. Indexing and 
amplification was performed using Illumina PCR primers 
InPE1.0 and InPE2.0 and primer indices. Pooled, indexed 
libraries were captured using an Agilent SureSelect Cus-
tom DNA kit targeting exons of 245 commonly mutated 
cancer genes (Agilent Technologies, Columbia, MD). 
Sequencing was done on Illumina’s Miseq sequencers. 
Variant calling was performed by Samtools mpileup and 
variants were annotated by the Annovar.
Gene expression analysis of microarrays
Total RNA was extracted from a panel of 8 gastric can-
cer cell lines (SB.mhdgc-1, SB.msgc-1 and cell lines 
purchased from ATCC) using RNeasy Mini Kit (Qia-
gen, Valencia, CA). RNA concentration and integrity 
were analyzed with Agilent 2100 Bioanalyzer system 
(Agilent Technologies, Columbia, MD). Biotinylated 
cRNA was generated with Illumina TotalPrep™-96 
RNA Amplification Kit (Life Technologies, Grand 
Island, NY). Biotinylated cRNA was then hybridized to 
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HumanHT-12 v4 Expression BeadChip (Illumina, San 
Diego, CA); array signal was normalized to expression 
levels of housekeeping genes and log2-transformed. 
Unsupervised hierarchical clustering analysis was con-
ducted using GeneSpring v12.6 (Agilent Technologies, 
Columbia, MD). Per-probe normalization was applied 
by subtracting the log2 signal intensity of the median 
value for a specific probe from the log2 signal inten-
sity of each cell line. Genes represented by more than 
one probe were collapsed by aggregating to the mean. 
Hierarchical clustering was then performed using 
GeneSpring default settings, specifically Euclidean 
similarity measures and Wards linkage rule. Analyze 
Single Experiment analysis option in the default Stand-
ard Data Analysis Workflows was used for analysis. 
The default workflow options (Threshold: 0; p value: 
1; Signals: both) were used for our analysis. Analyze 
networks (AN) algorithm with default metacore set-
tings was used for generation of biological networks. 
The networks were eventually prioritized based on the 
number of fragments of canonical pathways. The top 
network is shown in Fig. 2b.
Phospho‑immunoblot analysis
Gastric cancer cells were lysed with Cell Signaling lysis 
buffer (Cat#40–040, Millipore, Bellerica, USA). Pro-
tein concentration was determined via BCA analysis kit 
(ThermoScientific, Waltham, USA). For phospho-immu-
noblotting using p-ERK Thr202/Tyr204 (Cat#4376), 
p-AKT T308 (Cat#9275), p-PDK1 Ser241 (Cat#3438) 
approximately 50ug of protein was loaded, for total anti-
ERK (Cat#9101), AKT (Cat#C67E7), PDK1 (Cat#3062), 
and actin (Cat#4967, all Cell Signaling, Danvers, USA) 
5–10 µg, onto 4–20% SDS/Polyacrylamide gels. Proteins 
were transferred to nitrocellulose blotting paper via the 
dry HEP-OWL1 system (ThermoScientific, Waltham, 
MA). Bands were visualized via the Odyssey lumines-
cence scanner (Li-Cor, Lincoln, USA).
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Fig. 2 Characteristics of patient‑derived c.del1380CDH1 SB.mhdgc‑1 cancer cells. a Light microscopy image of c.del1380 CDH1 SB.mhdgc‑1 cells 
(10× magnification). b SB.mhdgc‑1 cells lack E‑cadherin expression but express CEA. Immunoflurescence of SB.mhdgc‑1 cells stained with anti‑E‑
cadherin (left) and anti‑CEA (right; both green), nuclei stained with DAPI (blue). Gastric cancer lines N87 and AGS (for E‑cadherin), BxPC3 and HeLa 
cells (for CEA) shown as positive and negative controls. c Karyotype and SKY images of SB.mhdgc‑1 cells show features consistent with human 
cancer cells including aneuploidy (such as in chromosomes 1 and 2) and chromosomal translocations (in chromosomes 3:5 and 4:8). d Light 
microscopy of c.del1380CDH1 SB.mhdgc‑1 cancer cells grown under ultra‑low attachment conditions in FBS‑free media. Top (14 days of culture), 
three dimensional multicellular spheroid (MCS) clusters with compact, amorphous center. Bottom (33 days of culture), c.del1380CDH1 SB.mhdgc‑1 
spheroids have rounded up, became more compact, and formed basal membranes (arrows; 20× magnification). e Patient‑derived SB.mhdgc‑1 cells 
harbor c.1380del CDH1 germline mutation. Deep sequencing of Hg19 CDH1 locus (chr16: 68,771,195‑68,869,444, NM_004360) in c.del1380CDH1 
SB.mhdgc‑1 spheroids (top) and SB.mhdgc‑1 cells 2D monolayer cells (bottom); 40 base sequences of 14 genomic DNA fragments around c.1380 are 
shown. Artifacts of alignment as identified by BWA are shown in blue
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Quantitative high‑throughput screening (qHTS)
High-throughput drug screening was conducted in 
patient-derived, low passage hereditary c.del1380A 
SB.mhdgc-1 gastric cancer cells and low passage 
SB.msgc-1 derived from a metastatic lesion of a ptient 
with sporadic gastric cancer; the methods have been 
described in detail previously [16]. In brief, assays were 
conducted in sterile, tissue culture-treated 1536-wells. A 
total of 500 cells per well in 5 μL of media were seeded. 
Immediately after dispensing the cells, 23 nL compound 
solution in DMSO was transferred using a Kalypsys (San 
Diego, CA) pintool. Plates were then covered and incu-
bated for 48  h. 3  μL CellTiterGlo assay reagent (Pro-
mega, Madison, WI) was added, plates were incubated 
for 30 min at room temperature, spun at 1000 rpm, and 
relative luminescence units (RLU) were quantified using 
a ViewLux Luminometer (PerkinElmer, Waltham, MA). 
The MIPE-oncology library 4.0 (MIPE: Mechanism Inter-
rogation PlatE) contains 1912 compounds known to 
modulate oncology targets, pathways, and phenotypes. 
Additional file  1: Table S1 lists individual compounds, 
mechanisms of action, stage of development, structure, 
and acquisition information. Compounds were tested in 
dose–response curves starting at a final concentration 
46  μM and threefold dilutions. The library was tested 
at 11 compound concentrations for qHTS as previously 
described [16, 17].
Hit selection from qHTS and reagents list
Activity of the compounds from the dose response qHTS 
screen was determined based on four dose response 
parameters: (1) % viability at the maximum concentra-
tion of compound tested (MAXR) as a measure of com-
pound efficacy; (2)  logAC50 after a four-parameter fit of 
a complete drug response curve as a measure of com-
pound potency; (3) curve response class (CRC) classifica-
tion from dose response HTS, in which normalized data 
is fitted to a 4-parameter dose response curves using a 
custom grid-based algorithm to generate curve response 
class (CRC) score for each compound dose response [17, 
18]. CRC values of −1.1, −1.2, −2.1, −2.2 are consid-
ered highest quality hits; CRC values of −1.3, −1.4, −2.3, 
−2.4 and −3 are considered inconclusive hits; and a CRC 
value of 4 are inactive compounds; and 4) Area Under the 
Curve (AUC), which is calculated using the trapezoidal 
rule over all measured responses [19]. (see Additional 
file  2: Table S2, for list of MAXR,  logAC50, CRC, AUC, 
for the compounds screened in each cell line).
Target enrichment analysis
Following selection of active compounds, we identi-
fied the annotated targets for these compounds and 
computed the enrichment for each target, compared to 
background, using Fishers exact test [20]. For this test, 
the background was defined as all the targets annotated 
in the MIPE collection. The p value from the test was 
adjusted for multiple hypothesis testing using the Benja-
min–Hochberg method [21].
Cell viability assay drug‑response profiles
The effects of select small molecule inhibitors and chem-
otherapy agents identified from the qHTS on prolifera-
tion were tested by seeding 5000 cells per well in 96-well 
plates and incubating them for 24  h before addition of 
drug. Increasing concentrations of drug were added 
to the wells in three replicates with DMSO as negative 
control. Plates were analyzed 72 h after addition of drug 
using the Promega Cell Titer Glo assay reagent (Pro-
mega, Madison, WI). Plates were read with  GloMax® 96 
Microplate Luminometer (Promega, Madison, WI), and 
the data analyzed using SoftMax version 5 and GraphPad 
Prism version (La Jolla, CA). Percent cell viability was 
calculated by normalizing raw luminescence values to 
vehicle-control (DMSO-treated) samples.
Apoptosis assay
Increasing concentrations of P-103, etoposide, and 
mitoxantrone (all Selleck Chemicals, Houston) were 
added to 5000 cells seeded the day prior in 96-well plates 
in three replicates with DMSO as negative control. Plates 
were analyzed 24 h after addition of drug using Caspase-
Glo® 3/7 Assay System (Promega, Madison, WI). Plates 
were read with  GloMax® 96 Microplate Luminometer 
(Promega, Madison, WI), and the data analyzed using 
SoftMax version 5 and GraphPad Prism version 7 (La 
Jolla, CA). For cell cytometric apoptosis measurements 
using fragmented DNA the template-independent addi-
tion of bromolated deoxyuridine triphosphates (Br-
dUTP) to free 3′-hydroxyl (OH) termini of double- and 
single-stranded DNA was determined using the Apo-
BrdU Kit (Cat. No. 51-6536KK; BD Biosciences, San Jose, 
CA). 1 × 106 cells were plated, the following day DMSO, 
PI-103, etoposide, and mitoxantrone were added and 
incubated for 24 h. Cells were harvested and stained with 
FITC-labeled anti-BrdU monoclonal antibody accord-
ing to the manufacturers instruction. Non-apoptotic (no 
Br-dUTP was detected) and apoptotic populations were 
measured on a BDFacsAriaII flow cytometer (BD Bio-
sciences, San Jose, USA).
Cell adhesion assay
Ratio of adherent versus floating cells at various times 
points after seeding was measured for SB.mhdgc-1 and 
SB.msgc-1 cells on regular 24-well tissues culture plates, 
and on 24-well plates coated with collagen I, fibronec-
tion, laminin I (all ThermoFisher Scientific, Waltham, 
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MA), and 96-well plates coated with vitronectin (R&D 
Systems, Minneapolis, MN). Cells were seeded in six 
replicates at 1.0 × 105 cells per well in 24-well plates and 
2 × 104 cells per well in 96-well plates and two independ-
ent cell counts in Nexcelom Auto T4 Hemacytometer 
cell chambers (Nexcelom, Lawrence, MA) were obtained. 
Time course ratios of adherent versus floating cells were 
graphed using GraphPad Prism version 7 (La Jolla, CA).
Results
Characteristics of hereditary diffuse gastric cancer 
c.del1380A CDH1 mutant SB.mhdgc‑1 cells
The patient is a 44-year old male who presented for 
management of metastatic diffuse gastric cancer. His 
sister and father were diagnosed with diffuse gastric 
cancer at the age of 44 and 72, respectively (Fig. 1). The 
patient, and other family members had been previously 
tested for germline CDH1 mutations and found to har-
bor a heterozygous c.1380delA variant in exon 10 of the 
CDH1 locus. The protein product is a 480-amino acid 
long (P461Lfs*20) variant of CDH1 (Additional file  3: 
Figure  S1), and is predicted to be disease causing and 
subject to nonsense-mediated RNA decay by Mutation-
Taster and SIFT prediction leading to loss of expression. 
A palliative paracentesis was performed; cytological 
conformation of cancer cells was confirmed and used to 
establish the c.1380delA CDH1 SB.mhdgc-1 cancer cell 
line.c.1380delA CDH1 SB.mhdgc-1 grow as a pleiomor-
phic, irregular shaped cells monolayers to near conflu-
ency (Fig. 2a). Cells displayed considerable heterogeneity 
without one morphological phenotype becoming domi-
nant after repeat passaging (>20 passages). Cells are able 
to raise daughter cells and cell islands both in early (<5), 
as well as later passages. Doubling time was prolonged 
between 72 and 84  h. Immunocytochemical staining 
shown in Fig. 2b demonstrates loss of E-cadherin expres-
sion in c.1380delA CDH1 SB.mhdgc-1 cells and strong 
(≥90% of cells) expression of the gastrointestinal tissue 
marker glycoprotein CEA. Multiple SKY karyotyping 
shows a diploid karyotype with frequent chromosomal 
aberrations including losses, duplications, and trans-
locations typically observed in cancer (Fig.  2c). Several 
translocations were validated by FISH, Additional file 1: 
Table S1 summarizes the main detected chromosomal 
abnormalities. We assessed next the ability of mono-
dispersed c.1380delA CDH1 SB.mhdgc-1 gastric cancer 
cells to self-assemble and form multicellular spheroids 
(MCS), both as a measure of their self-renewal ability 
and tumorigenicity as well as to investigate the possible 
impact the loss of CDH1 might have on self-aggregation 
and the ability to form cell-to-cell contact. Figure  2d 
shows different phases of MCS grown from c.1380delA 
CDH1 SB.mhdgc-1 cells over 6  weeks. To confirm that 
MCS and 2D monolayer cells maintained the same 
CDH1 genotype, we performed deep sequencing using 
the CLIA-approved OncoVar assay in both spheroids as 
well as monolayer c.1380delA CDH1 SB.mhdgc-1 cells 
confirming the unique c.1380delA CDH1 variant in both 
subpopulations (Fig. 2e). c.1380delA CDH1 SB.mhdgc-1 
cells initiated tumors upon implantation into nude mice 
which failed to grow beyond 5  mm (4  months). All fol-
lowing experiments, including drug screening, were per-
formed with c.1380delA CDH1 SB.mhdgc-1 cells grown 
as monoloyer.
The detection of the previously affirmed germline 
c.1380delA CDH1 germline variant in the derived cells, 
the loss of E-cadherin in combination with features of 
malignant transformation suggests the establishment of 
a de novo primary cell culture line from a patient with 
HDGC.
Gene expression analysis of c.1380delA CDH1 mutant 
SB.mhdgc‑1 cells shows upregulated ERK1‑ERK2 
and inositoltrisphosphat (IP3)/diacylglycerol (DAG) 
signaling in comparison to sporadic gastric cancer cells
To compare the loss of CDH1 due to germline mutations 
in gastric cancer cells derived from a HDGC patient to 
sporadic gastric cancer cells, we performed genome-wide 
microarray profiling in c.1380delA CDH1 SB.mhdgc-1 
and 7 sporadic gastric cancer cell lines using the Illu-
mina HumanHT-12 v4 platform. Microarrays were run 
in triplicates, only reads passing the manufacturers QA 
in all replicates were included. Metastatic hereditary 
diffuse gastric cancer c.1380delA CDH1 SB.mhdgc-1 
cells harbor distinct transcriptomic profile compared 
to a cohort of sporadic gastric cancer cell lines. There 
were 938 genes more than twofold differently regulated 
in the c.1380delA CDH1 SB.mhdgc-1 cells (p  <  0.05; 
FDR  <  0.1) with c.1380delA CDH1 SB.mhdgc-1 cells 
separating on unsupervised hierarchal cluster analysis 
of global gene expression profiling from sporadic gastric 
cancer cell lines (Fig.  3a). Gene ontology (GO) cellular 
process analysis of gene expression profile of c.1380delA 
SB.mhdgc.-1 gastric cancer cells ranked enrichment of 
ERK1 and ERK2 signaling first (p  <  10 E-8), out of the 
top 10 ranked processes three involved cellular organiza-
tion and cytoskeletal organization (p < 10 E-6; Additional 
file 4: Figure S2). To further detail signaling network per-
turbations selective for c.1380delA SB.mhdgc.-1 gastric 
cancer cells compared to sporadic gastric cancer cells, 
we generated biological networks using analyze networks 
(AN) algorithm with default settings ranking shortest 
paths algorithm by main parameters (1) relative enrich-
ment with uploaded profile of c.1380delA SB.mhdgc-1 
gastric cancer cells versus sporadic gastric cancer 
cell lines, and (2) relative saturation of networks with 
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canonical pathways with networks are prioritized based 
on the number of fragments of canonical pathways on 
the network. Figure 3b shows the top ranked ERK1/ERK2 
network (gScore 112.87; zScore 10.37; p value 1.23e-05) 
with MAPK pathway, inositol triphosphate (IP3)/diacyl-
glycerol (DAG), and alternative erb receptor signaling 
via FAK, c-Src, or protein kinase C most prominently 
enriched. Other secondary networks represented in 
gene expression profile of c.1380delA SB.mhdgc.-1 gas-
tric cancer cells include cytoskeletal regulators like actin, 
paxillin, or β-catenin.
To confirm above signal transduction aberrations 
observed on differential gene expression profiling of 
c.1380delA SB.mhdgc.-1 and sporadic gastric cancer 
cells, we first measured intracellular phosphatidylino-
sitol 4,5-bisphosphate (PIP2) levels, and its metabo-
lite phosphatidylinositol 3,4,5-trisphosphate (PIP3), 
as intermediaries of inositoltrisphosphat (IP3)/diacyl-
glycerol (DAG) signaling between c.1380delA CDH1 
SB.mhdgc-1 and sporadic SB.msgc-1 gastric cancer cells. 
SB.msgc-1 cancer cells were derived from a left liver 
lobe lesion of metastatic sporadic, moderately to poorly 
differentiated adenocarcinoma of the stomach with 
intestinal and signet ring cell features of a 44-years old 
female and has been previously described [14]. Tumor 
cells stained positive for Ecadherin and strongly posi-
tive (3+) for HER2 (Additional file  5: Figure  S3). Lev-
els of intracellular phosphoinositide metabolites were 
measured by quantitative immunofluorescence using 
anti-lipid phosphoinositide antibodies (Fig.  3c). Phos-
phatidylinositol 4,5-bisphosphate (PI(4,5)P2) is a sub-
strate for phospholipase C–G-protein coupled receptor 
pathway signaling intimately involved in intracellular 
calcium release and overall phosphoinositide metabolism 
Fig. 3 c.1380delA CDH1 SB.mhdgc‑1 harbors select transcriptomic alterations compared to sporadic gastric cancer cells. a Unsupervised hierarchi‑
cal cluster analysis and associated heat map of baseline transcriptomic profiles. Columns represent individual probes while rows represent individual 
cell lines. The color of each probe reflects  log2 ratio of normalized expression values for each cell line compared to the median from all cell lines (see 
scale, top 200 upregulated and 100 downregulated (FC > 2; p < 0.05) in c.1380delA CDH1 SB.mhdgc‑1 shown). b Most relevant network selective 
for SB.mhdgc‑1 cells by GeneSpring GX analyze networks (AN) algorithm using shortest paths algorithm with main parameters (1) relative enrich‑
ment and (2) relative saturation of networks with canonical pathways. Networks are prioritized based on the number of fragments of canonical 
pathways in the network. c c.1380delA CDH1 SB.mhdgc‑1 gastric cancer cells harbor increased phosphoinositide‑derived messengers. Immuno‑
fluoresence of SB.mhdgc‑1 and sporadic SB.msgc‑1 gastric cancer cells measuring anti‑phosphatidylinositol 4,5‑bisphosphate (top) and anti‑phos‑
phatidylinositol 3,4,5‑trisphosphate levels (bottom). Mean of staining intensity normalized to DAPI of 100 cells of SB.mhdgc‑1 and SB.msgc‑1 shown 
on the right. d Reduced cell adhesion including extracellular matrix substrate adhesion of c.1380delA CDH1 SB.mhdgc‑1 versus SB.msgc‑1 cells. 
Time course of ratios of adherent versus non‑adhered cells (student’s t test; two images were acquired of each triplicate and the mean taken). e 
Increased p‑ERK: total ERK and p‑AKT: total AKT protein expression ratios in c.del1380A CDH1 SB.mhdgc‑1 cells compared to sporadic gastric cancer 
cell lines. Immunoblots with antibodies indicated on the right
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[22]. Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)
P3)) is formed by PI 3-kinase. PI(4,5)P2 levels, and to a 
lesser degree, PI(3,4,5)P3 intermediaries were meas-
ured elevated in c.1380delA SB.mhdgc.-1 gastric can-
cer cells compared to SB.msgc-1 sporadic gastric cancer 
cells (Fig.  3c) commensurate with findings of compara-
tive gene expression profiling of hereditary c.1380delA 
SB.mhdgc.-1 cells. To examine if detected transcriptomic 
perturbations in cytoskeletal regulation in hereditary 
c.1380delA SB.mhdgc-1 cells measured by Gene Ontol-
ogy (GO) cellular process analysis and Analyze Net-
works (AN) algorithm might result in altered adhesion 
function, we compared next the ability of c.1380delA 
SB.mhdgc.-1 gastric cancer to SB.msgc-1 cells to adhere 
on regular non-treated tissue culture flasks, and then 
examined rescue by repeating adhesion experiments on 
plates coated with extracellular matrix molecules includ-
ing collagen I, fibronectin, and laminin. When measur-
ing the ratio of adherent versus non-adherent cells at 
2.5 and 5 h after seeding of cells, adhesion of c.1380delA 
CDH1 SB.mhdgc.-1 gastric cancer cells was substan-
tially reduced compared to CDH1 wild type sporadic 
SB.msgc-1 cells. The presence of extracellular matrix 
adhesion molecules rescued impaired adhesion of 
c.1380delA CDH1 SB.mhdgc-1 cells, albeit significantly 
less compared to SB.msgc-1 sporadic gastric cancer cells 
(Fig.  3d). We next measured signaling activity of the 
PI3K-AKT and MAPK pathway in hereditary c.1380delA 
CDH1 SB.mhdgc.-1 gastric cancer cells versus a panel of 
sporadic gastric cancer cell lines by determining ratios of 
phosphorylated Akt, PDK1, and ERK1/2 (MAPK42/44) 
to total Akt, PDK1, and ERK kinase levels. Phospho-
ERK-to-total ERK, and phospho-Akt-to-total AKT ratios 
were elevated in c.1380delA CDH1 SB.mhdgc.-1 gastric 
cancer cells compared to a panel of six heterogenous spo-
radic gastric cancer lines (Fig. 3e), a finding in line with 
above gene set enrichment analysis identifying ERK1/
ERK2 network as top network enriched in SB.mhdgc-1 
cells. Albeit not different to sporadic gastric cancer cell 
lines N87 and SNU16, c.1380delA CDH1 SB.mhdgc-1 
cells showed activation of the Akt-upstream regulator 
and PIP3 sensor 3-phosphoinositide dependent protein 
kinase-1 (PDK1, measured as serine 241 phosphoryla-
tion), a finding consistent with elevated PIP3 levels in 
SB.mhdgc-1 cells compared to SB.msgc-1 cells.
Overall, select signal transduction alterations in 
c.1380delA CDH1 SB.mhdgc-1 gastric cancer cells 
derived from differential gene expression profiling, phos-
phoinositide intermediary level measures, and immuno-
blotting suggest perturbations in MAPK kinase pathway, 
phosphoinositide-mediated signaling, as well as extracel-
lular matrix adhesion dysfunction enriched in c.1380delA 
CDH1 SB.mhdgc-1 gastric cancer cells compared to spo-
radic gastric cancer cell lines.
Dose response quantitative high‑throughput screening 
of c.1380delA CDH1 SB.mhdgc‑1 and sporadic gastric 
cancer cells SB.msgc‑1 with an oncology library identifies 
selective pharmacological vulnerabilities in hereditary 
diffuse gastric cancer cells
Adherent c.1380delA CDH1 SB.mhdgc-1 cells, derived 
from a patient with hereditary diffuse gastric cancer due 
a germline CDH1 mutation, and adherent SB.msgc-1 
gastric cancer cells, derived from a patient with sporadic 
gastric cancer, were screened in 1536-well microplates 
for growth inhibition using the MIPE 4.0 Oncology 
Library which includes 1912 oncology compounds 
which are either clinically approved or currently in late 
preclinical development. Full compound dose response 
curves starting from 46  µM and threefold dilutions 
were used to treat the cells for 48  h. Drug effects were 
quantitated by four different methods capturing effi-
cacy (MAXR, maximum response), potency  (LogAC50), 
or both, CRC scores (Additional file  6: Figure  S4), and 
area under the curve (AUC). The results of the dose 
response screening of the MIPE 4.0 oncology collec-
tion show that each cell line had distinct pharmacologi-
cal vulnerabilities regardless of the dose response curve 
parameter used to determine compound activity. Area 
under the curve (AUC) is a parameter often used to 
quantitate the effect of drugs because it integrates both 
efficacy and potency. Figure 4 shows a bubble chart, cor-
relation plot depicting both the number of compounds 
per drug class, as well as the overall AUC activity of 
the compounds within a target class for both cell lines. 
Drug class activities with  ≥2 standard deviations from 
the mean of ΔAUC(% AUC(c.1380delA SB.mhdgc-1/
SB.msgc-1) were considered significantly more active in 
the respective cell line. Using ΔAUC, drug classes with 
enriched activity against hereditary diffuse gastric can-
cer c.1380delA CDH1 SB.mhdgc-1 cells include mTOR, 
MEK, FAK, ROCK, and protein kinase C inhibitors, with 
aurora kinase inhibitors showing a trend towards greater 
activity, whereas bromodomain-containing protein 4 
(BRD4), phospho-diesterase (PDE5A) inhibitors, and 
to a lesser degree, HDAC and HER receptor inhibitors 
showed preferentially greater activity in the sporadic 
wild type CDH1 SB.msgc-1 cells. Using the MAXR (cell 
killing at highest tested drug concentrations) param-
eter as a measure of compound activities, the drug pro-
files and drug classes measured as active in the two cell 
lines were similar to those obtained using AUC (Addi-
tional file  7: Figure  S5A). Using potency  (logAC50) as 
a measure of compound activity, fewer drug classes 
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were significantly different between c.1380delA CDH1 
SB.mhdgc-1 and SB.msgc-1 cells: while topoisomerase II 
and AKT inhibiting agents were identified as preferen-
tially active, some of the previously differently observed 
drug classes like MEK, protein kinase C, or ALK inhibi-
tors were not measured as different activity profiles in 
the two cell lines (Additional file  7: Figure  S5B) when 
using  logAC50. When applying the most stringent cri-
teria for drug activity by combining both criteria high 
quality drug response curve (drugs yielding high quality 
CRCs including −1.1, −1.2, −2.1, and −2.2) and potency 
(Δ-log[AC50] (SB.mhdgc-1–SB.msgc-1)  <  1) and com-
paring drug activity profiles between c.1380delA CDH1 
SB.mhdgc-1 and SB.msgc-1 cells, compounds target-
ing mTOR, PI3KCA, and AKT1 were significantly (p 
value < 0.01) enriched as selectively active in hereditary 
diffuse gastric cancer versus sporadic SB.msgc-1 cells 
(Additional file  8: Figure  S6A). Box plots showing the 
logAC50 distribution of logAC50 for the compounds 
of targets showing enrichment as being more selec-
tively potent for c.1380delA CDH1 SB.mhdgc-1 shown 
in Additional file  8: Figure  S6B identifies activities of 
anti-mTOR, topoisomerase II, and tubulin inhibitors as 
most different between the two cell lines. Since dysregu-
lated gene expression of druggable targets can indicate 
dependency, and possibly pharmacological vulnerability 
in affected cells, we overlaid differential drug phenotype 
and gene expression changes (fold difference) between 
c.1380delA CDH1 SB.mhdgc-1 and SB.msgc-1 cells of 
known direct druggable targets of any of the compounds 
represented in the MIPE 4.0 Oncology Library. Only 52 
of the direct targets of compounds in the MIPE collec-
tion showed greater than twofold difference in expres-
sion levels between c.1380delA CDH1 SB.mhdgc-1 
and SB.msgc-1 cells. Using difference in potency (delta 
 logAC50) and maximum response percent viability upon 
treatment of both cell lines shown as overlaid boxplots 
in Additional file  8: Figure  S6C, the most distinct cor-
relations between dysregulated genes and pharmaco-
logical profile of c.1380delA CDH1 SB.mhdgc-1 versus 
SB.msgc-1 cells included anti-topoisomerase II and 
anti-microtubule (TUBB) regulation. As the above dif-
ferential screening approach missed common pharma-
cological vulnerabilities shared between c.1380delA 
a
Max Response SB.mhdgc-1
M
ax
 R
es
po
ns
e 
SB
.m
sg
c-
1
130
120
110
100
90
80
70
60
50
40
30
20
10
0
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
MaxResponse <30% for both cell lines
(314 compounds)
PS
MD
1
EG
FR
HD
AC
1
JA
K2
BC
L2
L1 AR ITK
CC
R5
CD
K4
TX
NR
D1
ST
AT
3
PD
E5
A
0
2
4
6
Target Class
-lo
gp
-v
al
ue
b
Fig. 4 Comparative quantitative high‑throughput screening (qHTS) using compounds from the MIPE Oncology 4.0 library identifies compounds 
with preferential activity against c.del1380A CDH1 SB.mhdgc‑1 cells compared to SB.msgc‑1 gastric cancer cells. a Bubble diagram of drug phe‑
notypes by compound class of SB.mhdgc‑1 versus SB.msgc‑1 cells depicting class activities (number of compounds per drug class) measured by 
area under the curve (AUC) (drug class activities ≥2 standard deviations from the mean of ΔAUC(% AUC(c.1380delA SB.mhdgc‑1/SB.msgc‑1) being 
considered significantly more active in the respective cell line). b Drug classes with activity in both c.del1380A CDH1 SB.mhdgc‑1 and SB.msgc‑1 
gastric cancer cells by maximum response (MAXR) <30%. Enrichment (number of active compounds in a target class relative to total number of 
compounds for that target class versus enrichment for each target, compared to background; Fishers exact test, 2‑tailed)
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CDH1 SB.mhdgc-1 and SB.msgc-1 cells, which may 
harbor valuable future therapeutic leads, we also exam-
ined activities screen results for active hits present in 
both cell lines using MAXR. There were a total of 314 
compounds which  ≥70% complete cell killing at high-
est drug concentration (Fig. 4b). Classes with significant 
enrichment (number of active compounds in a target 
class relative to the total number of compounds for that 
target class; computed enrichment for each target, com-
pared to background, using Fishers exact test; p < 0.01) 
included anti-EGFR and JAK2 inhibitors (Fig. 4b).
In summary, hereditary c.1380delA CDH1 SB.mhdgc-1 
have select pharmacological vulnerabilities which, in 
part, align with signal transduction perturbations and 
gene expression alterations detected in these cells.
Validation of candidate active compounds in c.1380delA 
CDH1 SB.mhdgc‑1 cells
Based on both the enrichment profile of preferentially 
active drugs as well as gene expression and signal trans-
duction aberrations in c.1380delA CDH1 SB.mhdgc-1 
gastric cancer cells, we selected the dual PI3K/mTOR 
inhibitor PI-103 and the topoisomerase II inhibitors 
etoposide and mitoxantrone as leads for further follow-
up. One of the other candidates targeting microtubule 
assembly and disassembly, anti-tuberin agent taxane, 
is already used in the management of advanced gastric 
cancer, including in hereditary diffuse gastric cancer, and 
we elected not to extend studies on this class of agents 
further. We first aimed to validate the increased activity 
of the dual PI3K/mTOR and topoisomerase II inhibitors 
in hereditary c.1380delA CDH1 SB.mhdgc-1 gastric can-
cer cells in an extended panel of sporadic gastric cancer 
cell lines. Figure  5a shows full 10-point dose response 
curves of PI-103, etoposide, and mitoxantrone confirm-
ing select sensitivity of hereditary c.1380delA CDH1 
mutant SB.mhdgc-1 gastric cancer cells compared to 
most sporadic gastric cancer cells (up to 100- to 1000-
fold lower GI50 measurements compared to SNU-16 
or SB.msgc-1 cells). Next, we examined apoptosis levels 
upon treatment in c.1380delA CDH1 SB.mhdgc-1 and 
sporadic gastric cancer lines. Levels were initially meas-
ured via a caspase-3 and 7 chemoluminescence screening 
assay at 1  µmol drug treatment which showed elevated 
levels of activated caspase-3 and -7 in c.1380delA CDH1 
SB.mhdgc-1 cells (Additional file  9: Figure S7). Flow 
cytometry analysis of cell death measured by labeling 
DNA breaks with FITC-dUTP confirmed increased frac-
tion of BrU positive cells in mitoxantrone, etoposide, 
and PI-103-treated hereditary c.1380delA CDH1 mutant 
SB.mhdgc-1 gastric cancer cells showed increased cell 
death compared to sporadic gastric cancer cells (Fig. 5b). 
These findings, in line with results of above qHTS screen 
result, may hence provide possible leads for future pre-
clinical, and clinical, studies.
Discussion
Recent large-scale molecular subtyping efforts have 
opened novel individualized treatment avenues for gas-
tric cancer [23–25]. For example, patients with meta-
bolic subtype of gastric cancer derived from large gene 
expression profiling of multiple cohorts of clinical gas-
tric cancer specimens show improved clinic outcome 
upon treatment with 5-FU [23]. While cancer cells of 
the metabolic subtype were measured more sensitive 
to 5-FU, gastric cancer cells of the mesenchymal sub-
type responded to a greater degree to PI3K/mTOR inhi-
bition [23]. Similarly, the recently released data from 
The Cancer Genome Atlas (TCGA) initiative suggests 
genomically defined leads, for example, of increased sen-
sitivity to receptor tyrosine kinase or cell cycle modulat-
ing agents in the chromosomal unstable (CIN) identified 
gastric cancers, or increased sensitivity to PI3K kinase, 
JAK2, and immune checkpoint blockade in the EBV posi-
tive subtype [25]. In contrast, leads for drug sensitivities 
unique to familial gastric cancer due to germline CDH1 
mutations are to date largely derived from a synthetic 
lethality and drug screen in an isogenic CDH1 knock-
out breast fibroblast model (MCF10A CDH1(−/−)) [12], 
CDH1-negative systems overexpressing wild type ver-
sus mutant forms of CDH1 [26, 27], or correlative tissue 
studies of the early unique T1a lesions of prophylactic 
gastrectomy specimens [8, 10]. That hereditary diffuse 
gastric cancer (HDGC) due to germline CDH1 variants, 
and sporadic gastric cancers with somatic CDH1 pertur-
bations are unique subtypes of gastric cancer, likely to 
harbor different drug sensitivity profiles and hence offer 
opportunities for genotype-directed personalized treat-
ment approaches, is supported by a number of observa-
tions; for example, in a detailed CDH1 profiling effort of 
174 sporadic and 72 familial gastric cancer specimens 
Corso et  al. reported significant differences in clini-
cal outcomes depending on presence and type of CDH1 
alternation with the worst survival rates observed across 
all examined gastric cancers in cases with structural 
CDH1 defects and in particular in familial tumors [11]. 
Or, eleven percent of the 205 primary gastric adenocar-
cinoma, examined as part of the TCGA effort, harbored 
somatic mutations in the CDH1 gene, which occurred 
nearly exclusively in the genomically stable (GS) gastric 
cancer subtype (37% of GS cases) which, by far, com-
prised of the largest number of cancers with diffuse his-
tology [25].
In order to identify treatment leads selective for the 
HDGC subtype due to CDH1 germline mutations of gas-
tric cancer, we derived a primary tissue culture line from 
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an HDGC patient with a c.1380delA CDH1 truncating 
germline mutation leading to loss of CDH1 expression, 
and compared the transcriptomic profile and drug sen-
sitivity profile of these cells to a panel of sporadic gas-
tric cancer cells. GO analysis identified upregulation of 
ERK and phosphoinositide-mediated signaling network 
processes in hereditary c.1380delA CDH1 SB.mhdgc-1 
gastric cancer cells which showed selective sensitivities 
to different drug classes including mTOR, MEK as well 
as c-Src, FAK, or topoisomerase II inhibiting agents. 
These findings of select drug response profiles of heredi-
tary SB.mhdgc-1 gastric cancer cells to MEK and mTOR 
Fig. 5 c.1380 CDH1 SB.mhdgc‑1 gastric cancer cells show vulnerabilities to toposisomerase II and PI3K/mTOR inhibition. a Drug response curves of 
a panel of gastric cancer cell lines treated with a range of concentrations of mitoxantrone, etoposide (both TOPO2A inhibitors), or PI‑103 (dual class 
IA phosphatidylinositol 3 kinase/mTOR inhibitor) for 72 h. X-axis indicates log [concentration] tested, y-axis indicates cell viability percentage nor‑
malized to vehicle‑control samples. Mean cell viability values are plotted with standard error of the mean (SEM) from at least 2 independent experi‑
ments done in triplicate. b Rate of apoptosis induced by 24‑h treatment of 1 µM etoposide, mitoxantrone, or PI‑103 normalized to DMSO‑treated 
samples in sporadic gastric cancer SNU‑16 and hereditary c.1380delA SB.mhdgc‑1 cells. Flow cytometry profiles of FITC‑labeled anti‑BrdU staining of 
3′‑hydroxyl (OH) termini of double‑ and single‑stranded DNA, relative BrdU fractions normalized to DMSO‑treated control shown on the right
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inhibition, in combination with gene expression dysregu-
lation of ERK and phosphoinositide-mediated signaling 
networks, also appear to be in line with elevated phos-
pho-ERK: total ERK and phospho-Akt (T308): total Akt 
ratios observed as a measure of dysregulated signal trans-
duction activity in SB.mhdgc-1 cells. Additionally, these 
results, in part, overlap with data obtained from compar-
ative gene expression profiling, synthetic RNA lethality 
and drug screening in the isogenic MCF10A CDH1(−/−) 
breast fibroblast model as well as prior large-scale gene 
profiling studies of sporadic clinical gastric cancer speci-
mens [12, 23, 28].
Similar to the MCF10A CDH1(−/−) mutant cells, 
c.1380delA CDH1 SB.mhdgc-1 gastric cancer cells 
showed altered gene expression of genes involved in cel-
lular component organization, cytoskeletal organization, 
and cell adhesion (Additional file 4: Figure S2), including 
microtubule nucleation involving genes like TUBB2 [28]. 
We found c.1380delA CDH1 SB.mhdgc-1 cells sensitive 
to taxanes targeting TUBB1 as well as agents targeting 
mitosis like the aurora kinase inhibitors, a finding also 
made by Telford and colleagues in the MCF10A CDH1 
(−/−) system [12, 29]. Elevated phosphoinositide signal-
ing, both by direct detection of PI(4,5)P2 and PI(3,4,5)P3s 
messenger intermediates as well as by network analysis 
of differential gene expression profiling may be a conse-
quence of increased GPCR signaling, which was the most 
enriched functional cluster (enrichment score = 10.01) in 
the synthetic lethality screen and confirmed by increased 
sensitivity to JAK2 inhibition, an immediate downstream 
effector kinase of GPCR signaling complexes, in the iso-
genic MCF10A CDH1 (−/−) system studied by Telford 
et al. [12]. Overall, drug sensitivities with overlap to Tel-
ford and colleagues’ findings in the CDH1(−/−) isogenic 
mutant MCF10A model include inhibitors of the PI3K/
mTOR axis, including PI-103 followed up in our valida-
tion studies, mTOR, aurora kinase inhibitors as well as 
inhibitors of c-Src kinase. Our findings are also in line 
with the characteristics, both on a molecular and drug 
sensitivity level, of a large gene expression profiling effort 
across 258 tumors which identified three subclasses of 
gastric cancer [23]. In this large study of well-validated 
patient specimens, gene expression analysis identified 
three subgroups, mesenchymal, proliferative and meta-
bolic, based on transcriptomic differences. The mesen-
chymal subtype most frequently harbored diffuse gastric 
cancers (up to 92.5%), showed cell adhesion and cell 
motility as well as focal adhesion and ECM receptor gene 
expression aberrations and displayed sensitivity to inhibi-
tors of the PI3K/AKT pathway. These tumors were fre-
quently hyper-methylated and of high grade and appear 
to be most similar to the genomically stable (GS) subtype 
by TCGA which consists of 75% Lauren classification 
type diffuse tumors, which has the highest rate of CDH1 
mutations, as well as frequent variants involving genes 
of cytoskeletal, cell polarity, and cellular component 
organization, both findings in line with the GO process 
analysis and drug phenotype in the c.1380delA CDH1 
SB.mhdgc-1 cells [23, 25]. On the other, there were also 
significant differences between the pharmacological 
profile of MCF10A CDH1 (−/−) mutant cells reported 
by Telford and coworkers and the drug phenotype of 
c.1380delA CDH1 SB.mhdgc-1 in our study. Among 
these, for example, sensitivity to MEK or EGFR inhibition 
was not seen in E-cadherin deficient MCF10A cells and 
sensitivity to the c-Src kinase inhibitor saracatinib was 
only shown at one of the three concentrations tested to 
be significant between the CDH1 MCF10A isogenic cell 
line pair with overall generally a more modest effect on 
cell viability [12]. Also, there was discordancy between 
the sensitivities to HDAC inhibitors and anti-apoptosis 
inhibitors to BCL2 and XIAP between the two systems. 
We attribute these differences to the more evolved stage 
of the patient-derived c.1380delA CDH1 SB.mhdgc-1 
cells compared to the MCF10A system. In the sentinel 
studies of Humar and colleagues, who examined signal 
transduction aberrations of the T1a stage with phospho-
immunohistochemistry in a family with a c.1008G>T 
CDH1 germline mutation, detailed pathology analysis 
showed that deficiency in E-cadherin is sufficient to ini-
tiate diffuse gastric cancer in the absence of hyperpro-
liferation and that early intramucosal signet-ring cell 
carcinoma (SRRC) is initially slow proliferating in the 
upper neck of the gastric glands with loss of expression of 
junctional molecules including actin, p120, or Lin-7 hom-
ologue A of the cell polarity complex [9, 10]. Expansion 
and progression beyond the early HDGC base is associ-
ated with c-Src kinase activation, including activation 
of downstream effectors FAK and signal transducer and 
activator of transcription 3 (STAT3), and described as 
one of the sentinel events of progression beyond the gas-
tric mucosa and transformation to poorly differentiated 
cells and the development of an EMT phenotype [10]. 
It is thus perceivable that the MCF10A system, which is 
not tumorigenic per se and has no oncogenic addiction, 
represents the very early intramucosal T1a stage in the 
slow proliferating phase with no, or limited, response to 
inhibitors c-Src inhibitors but capturing the perturba-
tions associated with defective CDH1 adhesion and cell 
polarity signaling, whereas the transformed c.1380delA 
CDH1 SB.mhdgc-1 cells derived from the ascites of the 
HDGC patient with diffuse gastric cancer are depend-
ent on c-Src, MAPK kinase, or other late occurring signal 
transduction signaling aberrations [12, 28]. It is known 
that elevated c-Src or MAPK signaling pathways are 
involved in the activation of EMT transcription factors 
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[30–32]. Thus, while previous results including pharma-
cological leads from the isogenic E-cadherin deficient 
MCF10A model, or from a study in a CDH1 null dros-
ophila model, might be mostly applicable to the early, 
intramucosal T1a stage, we propose that leads derived 
from patient-derived c.1380delA CDH1 SB.mhdgc-1 cells 
capture later tumor stages shifting from a drug profile 
with primarily chemopreventative merit to a therapeutic 
one. The anecdotal use of anti-EGFR therapy with cetuxi-
mab in HDGC patients with advanced gastric cancers 
applied by some medical oncologists in the field appears 
to be in line with the detected sensitivities to EGFR, PI3K 
and MEK inhibition as well as elevation of MAPK kinase 
signaling in c.1380delA CDH1 SB.mhdgc-1 cells. Similar 
to KRAS wild type colon cancer, in the absence of con-
stitutively active RAS reduction of upstream input to 
the MAPK and PI3 kinase signal transduction pathways, 
EGFR inhibition might have merit as a molecular ther-
apy option which might be improved by the use of select 
downstream mTOR inhibition considering alternative 
non-erb receptor ligand activation of the PI3K pathway 
via increased phosphoinositol-mediated signaling, c-Src 
or protein kinase C signaling via ERK-mediated release of 
TSC1/2 and mTORC1 inhibition.
Together, combined comparative gene expression pro-
filing and qHTS in patient-derived hereditary c.1380delA 
CDH1 SB.mhdgc-1 cells may open new avenues to 
improved individualized treatment options for familial 
gastric cancer.
Conclusion
Hereditary diffuse gastric cancer due to CDH1 ger-
mline mutations has to date largely escaped the benefits 
of the personalized medicine approach. While signifi-
cant progress with regard to improvements in screening, 
surveillance, and risk reducing interventions has been 
made, HDGC patients affected by advanced gastric can-
cer have few effective treatment options, and receive, 
in large, despite the significant clinicopathological and 
genetic differences, the same systemic treatment options 
like patients affected by sporadic gastric cancer. Using 
the patient-derived c.1380delA CDH1 SB.mhdgc-1 and 
SB.msgc-1 tissue culture lines, and an extended panel of 
sporadic gastric cancer cell lines, combined comparative 
gene expression profiling and qHTS drug screening with 
a large oncology library identified leads with selective 
activity in familial gastric cancer cells occurring in the 
context of CDH1 germline mutations. Some of the vali-
dated leads have regulatory approval for other oncology 
indications, and thus can be expeditiously translated into 
early clinical trial testing possibly opening new avenues 
to improved treatment options for patients with familial 
gastric cancer.
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stomach SB.msgc‑1. Immunohistochemical staining at magnification ×20, 
inlet ×40.
Additional file 6: Figure S4. Diagrams of different dose responses and 
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c.1380delA SB.mhdgc‑1 versus SB.msgc‑1 gastric cancer cells identified by 
comparative qHTS screening with the MIPE Oncology 4.0 library. A, Bub‑
ble diagram of drug phenotypes by compound class of SB.mhdgc‑1 ver‑
sus SB.msgc‑1 cells depicting class activities (number of compounds per 
drug class) measured by maximum response (max response SB.mhdgc‑1 
/ max response SB.msgc‑1). B, Bubble diagram comparing drug activities 
measured by potency  (logAC50SB.mhdgc‑1 versus  logAC50SB.msgc‑1).
Additional file 8: Figure S6. A, Target enrichment for compounds with 
CRC −1.1, −1.2, −2.1, or −2.2 and delta  logAC50 (SB.mhdgc‑1  logAC50–
SB.msgc‑1  logAC50) < −1. −log p values were calculated as described 
in materials and methods based on the total number of compounds 
targeting a gene or mechanism. B,  LogAC50 distributions of compounds 
that show CRC −1.1, −1.2, −2.1, or −2.1 and logAC50 <−1 organized by 
enriched target class in c.1380delA CDH1 SB.mhdgc‑1 versus SB.msgc‑1 
gastric cancer cells. Box plots of median  logAC50 values of select target 
classes showing enrichment in c.1380delA CDH1 SB.mhdgc‑1 (red plots) 
and SB.msgc‑1 (blue plots). C, Concomitant dysregulation of target 
genes and selective activity of MIPE compounds in c.1380delA CDH1 
SB.mhdgc‑1 versus SB.msgc‑1 gastric cancer cells. Genes with greater than 
two‑fold expression difference in c.1380delA CDH1 SB.mhdgc‑1 com‑
pared to SB.msgc‑1 cells and which are direct targets of compounds in 
MIPE Oncology 4 are shown. Genes that are downregulated in c.1380delA 
CDH1 SB.mhdgc‑1 compared to SB.msgc‑1 cells are represented by green 
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Additional file 9: Figure S7. Increased induced cell death upon treat‑
ment with topoisomerase II and dual PI3K/mTOR in hereditary c.1380delA 
CDH1 SB.mhdgc‑1 versus sporadic gastric cancer cell lines. Caspase 3/7 
levels after 24 h of treatment with 1 µM mitoxantrone, 1 µM etoposide, 
or 1 µM PI‑103 normalized to DMSO‑treated control is shown (standard 
errors of the mean from at least 2 independent experiments done in 
triplicate shown).
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